Riktkurs.nu
EN | SV
There is a problem with the stock price data. Our supplier is working to solve the issue.
CalliditasMid CapCellavision
Stockholm Stock Exchange | Mid Cap
Camurus
+55.47%
Latest
+44.49%
3 months
Handelsbanken Capital MarketsPareto SecuritiesNordea MarketsDNBCarnegieBryan GarnierJefferiesHandelsbankenDNB Markets

Price Targets For Camurus

AnalystPrice TargetDateUpside
Handelsbanken Capital Markets500 SEKNov 13
+55.47%
Pareto Securities427 SEKNov 10
Nordea Markets467 SEKNov 10
DNB380 SEKJul 19
Carnegie335 SEKJul 19
Bryan Garnier320 SEKFeb 14
Jefferies205 SEKApr -22
Handelsbanken235 SEKDec -21
DNB Markets275 SEKNov -21

About The Company

Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases.
Wikipedia

The information on Riktkurs.nu is for general information purposes only. Riktkurs.nu makes no guarantees of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to Riktkurs.nu or the information, products, services, or related information on Riktkurs.nu for any purpose. The recipient is recommended to complete his or her decision basis with the material deemed necessary. We reserve us for all types of errors as well as any malfunctions of the website. The information on Riktkurs.nu should not be seen as a recommendation to buy or sell a security.
© Riktkurs.nu 2023